Vistagen Therapeutics, during its fiscal year 2024 third quarter financial results call, provided updates on its clinical programs and financial status. The company, which specializes in developing treatments for psychiatric and neurological disorders, announced the upcoming initiation of Phase 3 trials for its lead program, fasedienol, aimed at treating social anxiety disorder (SAD).
Vistagen also discussed its other programs, including itruvone for major depressive disorder and PH80 for women's health indications. The financial report showed a decrease in research and development costs, an increase in general and administrative expenses, and a cash reserve of approximately $126.6 million. Additionally, Vistagen filed a new shelf registration statement to support future financial strategies.
Key Takeaways
- Vistagen is preparing to launch Phase 3 trials for fasedienol for SAD in the first half of 2024.
- A repeat dose study of fasedienol is set to begin in the second half of the year to evaluate safety and efficacy.
- The company reported a decrease in research and development expenses and an increase in general and administrative expenses.
- Vistagen's cash and cash equivalents stood at $126.6 million as of December 31, 2023.
- The company has filed a shelf registration statement for potential future financial flexibility.
Company Outlook
- Vistagen is advancing its clinical programs with a focus on fasedienol for SAD and is optimistic about its potential.
- The company is exploring the possibility of obtaining breakthrough therapy designation for fasedienol based on preclinical data.
Bearish Highlights
- There is an increase in general and administrative expenses, which may impact profitability.
Bullish Highlights
- Vistagen has a strong cash position to support its clinical development programs.
- The company is hopeful about the improved design and execution of its Phase 3 trials.
- Vistagen has already secured fast-track designation and is considering pursuing breakthrough therapy designation.
Misses
- No specific financial performance metrics, such as revenue or earnings per share, were discussed in the provided summary.
Q&A Highlights
- The company addressed the potential for fasedienol to receive breakthrough therapy designation.
- Vistagen discussed the abuse potential of benzodiazepines and its efforts to demonstrate fasedienol's differentiated safety profile.
- The company expressed confidence in the non-abusable profile of fasedienol and its accessibility for patients online.
Vistagen Therapeutics, with ticker VTGN, remains focused on advancing its pipeline of treatments for psychiatric and neurological disorders. The company's financial position appears stable, with a substantial cash reserve and strategic plans for future financial flexibility. With upcoming clinical trials and a potential breakthrough therapy designation on the horizon, Vistagen aims to make significant strides in the treatment of social anxiety disorder and other conditions.
InvestingPro Insights
Vistagen Therapeutics (VTGN) has shown some intriguing financial metrics and market performance in recent months. Here are some key insights based on InvestingPro data:
- The company's market capitalization stands at $145.67 million, reflecting its current market valuation.
- Revenue growth has been impressive, with an increase of 386.35% over the last twelve months as of Q3 2024. This significant growth might indicate the company's potential in scaling up its operations and commercializing its clinical programs.
- Despite the substantial revenue growth, Vistagen's current P/E ratio is -2.20, and the adjusted P/E ratio for the last twelve months as of Q3 2024 is -4.13, suggesting that the company is not yet profitable.
InvestingPro Tips for Vistagen provide a deeper understanding of the company's financial health and future prospects:
1. Vistagen holds more cash than debt on its balance sheet, which is a positive sign for investors looking for financial stability in the company.
2. Analysts anticipate sales growth in the current year, which could be a driving factor for future stock performance.
For readers interested in a more comprehensive analysis, there are additional InvestingPro Tips available for Vistagen. These include insights into the company's cash burn rate, profitability expectations, and stock performance over various periods. Subscribers can access a total of 9 InvestingPro Tips for Vistagen, offering a detailed outlook on the company's financial situation and market potential.
To delve into these additional insights, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro. This offer can provide valuable guidance for those closely following Vistagen's journey in the competitive biotech industry.
Full transcript - VistaGen Therapeutics Inc (NASDAQ:VTGN) Q3 2024:
Operator: Greetings and welcome to Vistagen Therapeutics' Fiscal Year 2024 Third Quarter Financial Results and Corporate Update. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Mark McPartland, Senior Vice President, Investor Relations at Vistagen. Thank you. you may begin.
Mark McPartland: Thank you, Doug. Good afternoon, everyone and welcome to Vistagen's fiscal year 2024 third quarter corporate update conference call and webcast. This afternoon we filed our quarterly report and issued a press release providing an overview of our recent third quarter results and our neuroscience pipeline development. We encourage you to review the release, which can be found in the Investors section of the Vistagen website. During today's call, we will make forward-looking statements regarding our business based on our current expectations and information. Forward-looking statements speak only as of today and except as required by law, we do not assume any duty to update in the future any forward-looking statement made today. Of course forward-looking statements involve risks and uncertainties and our actual results could differ materially from those anticipated by any forward-looking statements we make today. Additional information concerning risks factors that could affect our business and financial results are included in our fiscal year 2024 third quarter Form 10-Q for the period ending December 31, 2023, and in future filings that we make with the SEC from time to time, all of which are or will be available on our website and the SEC's website. Now with that taken care of I'd like to thank and welcome all of our stockholders, analysts and everyone taking an interest in Vistagen. I'm joined on the call today by Shawn Singh, our Chief Executive Officer; Cindy Anderson, our Chief Financial Officer; and Josh Prince, our Chief Operating Officer. Shawn will provide an overview of our recent results and our progress across our key pipeline programs. A brief opportunity for questions from our sell-side analysts will follow the prepared remarks. I would like to remind everyone this call is being webcast and will be available for replay after completion. The replay link can be found in the Investor events section of the Vistagen website. I would now like to turn the call over to our Chief Executive Officer, Shawn Singh. Shawn?
Shawn Singh: Thank you, Mark, and good afternoon, everyone. Thank you for joining our call today. Here at Vistagen, we are pioneering neuroscience, with an intention to deliver first-in-class therapies for psychiatric and neurological disorders, where there are few, if any, adequate and differentiated FDA-approved treatment options to satisfy the widespread needs of patients whose mental health and whose well-being are adversely affected by their disorders. Each of our clinical stage neuroscience product candidates is designed with the potential to establish new standards of care and make meaningful differences in how patients manage their disorders to improve their daily lives. Within the last few months, we've seen a renaissance in neuroscience, marked notably by pharma M&A in the neuropsychiatry space, valued at about $23 billion. We are encouraged that novel, late-stage, neuroscience-derived product candidates with differentiated safety profiles have stimulated renewed interest in large-market neuropsychiatry programs with the potential to change lives. We believe each of our clinical neuroactive pherines, led by fasedienol for the acute treatment of social anxiety disorder, is anchored in novel neuroscience and has the potential to produce differentiated product profiles across multiple and diverse large-market therapeutic areas with high need for innovation and high need to transform the standards of care, including anxiety, depression, women's health and other disorders. Today, we'll briefly discuss our progress and plans for three of these -- three of our five pherine assets in our clinical-stage neuroscience pipeline, facadienol, itruvone, and PH80. As noted, our lead clinical-stage program involves fasedienol, and it's aimed at transforming the treatment paradigm for adults affected by social anxiety disorder, or SAD, which currently affects the lives of about 10% of the US adult population, with very high opportunity costs in their daily life. While the prevalence of SAD continues to grow, there's still no FDA-approved, patient-tailored, acute treatment option to help individuals with SAD rapidly and safely address their anxiety when their stressors are upon them in their daily life. With the positive results from our PALISADE-2 Phase 3 trial reported last year, and a strong balance sheet, we're fully focused on advancing our PALISADE Phase 3 development program in SAD, with preparations to initiate this year all key remaining studies planned for that program. Since our last conference call in November, our team has been diligently focused on the preparations necessary to initiate PALISADE-3, which will be our next Phase 3 clinical trial of fasedienol for the acute treatment of anxiety in adults with social anxiety disorder. That remains on track to begin in the first half of 2024. That will be followed by PALISADE-4 to be initiated in the second half of this year. PALISADE-3 and PALISADE-4 will be similar to our successful PALISADE-2 Phase 3 trial. Both trials will involve a public speaking challenge in a clinical setting with patient reported outcomes on the Subjective Units of Distress Scale or SUDS as the primary efficacy endpoint. We believe either PALISADE-3 or PALISADE-4 if successful, together with the positive results from PALISADE-2 may establish substantial evidence of effectiveness of fasedienol in support of a potential NDA submission for the acute treatment of anxiety in adults with SAD. Last year we accomplished something that to our knowledge had never been achieved and that is to demonstrate positive Phase 3 results in an anxiety study with a drug candidate that does not need to be taken up systemically or act directly on neurons in the brain. We look forward to getting back into the clinic soon with PALISADE-3 to continue driving on our mission to deliver a first-in-class therapy in a large neuropsychiatry market in need of differentiated fast-acting therapies without the risk of sexual side effects, weight gain, or abuse liability concerns. Beyond fasedienol in our Phase 3 program in SAD we are continuing to explore various ways to unlock the significant potential of itruvone asset as a differentiated new therapy for major depressive disorder or MDD. Preparations and planning for potential US Phase 2B trial of itruvone model therapy in MDD are ongoing. Again our mission in this large and unfortunately increasing neuropsychiatry market is to deliver a differentiated therapy to transform the standard of care without the risk of sexual side effects, weight gain or abuse liability concerns. We also see great potential in our rapid onset hormone-free PHAD nasal spray. Its potential is anchored in the previously unreported positive results from two trials in women's health indications that we announced last year. First is a treatment for vasomotor symptoms or hot flashes due to menopause and next, for the management of premenstrual dysphoric disorder or PMDD. PHAD showed statistically significant results in both studies. We are preparing to conduct non-clinical studies necessary to submit a USIND to facilitate further Phase 2 clinical development of PHAD for women's health indications including the treatment of patients with moderate to severe vasomotor symptoms or hot flashes that are due to menopause. I'll now turn the call over to our CFO, Cindy Anderson to summarize some of the highlights from our financial results for the third quarter of our fiscal '24. Cindy?
Cindy Anderson: Thank you, Shawn. As Shawn mentioned, I will highlight a few financial results from our fiscal year 2024 third quarter. I also encourage everyone to review our quarterly report on Forum 10Q filed with the SEC earlier this afternoon, for additional details and disclosures. Research and development expense was $4.5 million and $6.9 million for the three months ended December 31, 2023 and 2022 respectively. The decrease in R&D expense was primarily due to a decrease in clinical and development expenses related to the timing of such expenses incurred in our Phase 3 trials of fasedienol and FAD. General and administrative expense was $3.8 million for the three-month period ended December 31, 2023 compared to $3.1 million for the prior period. The increase is primarily due to the increase in compensation-related expenses. Our net loss attributed to common shareholders was $6.3 million and $9.8 million for the three months ended December 31, 2023 and 2022 respectively. At December 31, 2023, we had cash and cash equivalents of approximately $126.6 million. I will also note that this afternoon as customary for development stage companies in our sector, we filed a new shelf registration statement on Form S3 with the SEC to renew a previous S3, which was set to expire next month. Shelf registration statements on Form S3 are standard in our industry and are intended to provide us with broad flexibility to improve our balance sheet in the future as may be needed. As a reminder, please refer to our core report on Form 10-Q filed today with the SEC for additional details and disclosures. I will now turn the call back over to Shawn.
Shawn Singh: Thanks, Cindy. So as we wrap up today's call, I want to emphasize that we are very proud and very excited to be focused on reaching another key corporate milestone in the near term. That's the initiation of our PALISADE-3 Phase 3 trial of fasedienol for the acute treatment of anxiety in adults with SAD. We will progress through the next phases of our core corporate development strategies with confidence in our team's expertise to execute our PALISADE Phase 3 clinical program of fasedienol and SAD, the potential of our robust pipeline for multiple and diverse psychiatric and neurological disorders, and our steadfast commitment to pioneering neuroscience to develop and commercialize truly differentiated treatment solutions. So on behalf of our whole team here at Vistagen, I want to thank you for your continued support.
Mark McPartland: Thank you, Shawn. Operator, we would now like to turn the call over for questions from the sell-side analysts participating on the call today.
Operator: [Operator instructions] Our first question comes from the line of Paul Matisse with Stifel. Please proceed with your question.
UnidentifiedAnalyst: Hi, this is Julian on for Paul. Thanks so much for taking our question. Just a quick one for me; are you still planning on doing a repeat dose study for fasedienol in SAD? And if so, would you be able to provide any color on that? Thanks so much.
Shawn Singh: You bet. Thanks, Julian. Yeah, we are going to do a repeat dose study. It'll be similar in design to PALISADE-3 and to PALISADE-4, and thus obviously by extension PALISADE-2. It'll be smaller and it'll assess the safety and potential benefit of a second dose of fasedienol that is administered within 10 minutes after the first dose and prior to public speaking challenge. So similar study design, similar endpoint, obviously much smaller and the result of that study, part of it is in agreement with FDA, especially as to any potential safety issue, which we don't anticipate any with repeat dosing, but it really could inform the labelling and provide some guidance as to whether or not a second dose administered within 10 minutes, which might be the case in a real-world setting, is safe and as we anticipated, could be again -- could provide any potential benefit for some patients. So we'll prepare to initiate that study in the second half of this year as we've guided.
UnidentifiedAnalyst: Excellent. Thanks so much.
Operator: Our next question comes from the line of Andrew Tsai with Jefferies. Please proceed with your question.
Andrew Tsai: Hey, thanks. Good afternoon. Appreciate you taking my question. So maybe the first one on PALISADE-3, PALISADE-4, you're employing obviously some studying improvements to those programs. So could it be fair to assume that the SUDS separation in those studies could be even greater than what you saw in PALISADE-2 because as you're mitigating for placebo effect, could you be further maximizing the drug effect?
Shawn Singh: Well, thanks, Andrew. As you mentioned, we've done quite a few things to further de-risk the Phase 3 program and a lot of lessons learned on the other side of the prior studies and obviously this is not now a study design and an endpoint that sites and investigators are seeing after a pretty long hiatus in the space of a couple decades. So the things that we've done to improve surveillance, improve and further de-risk execution of the program, certainly that's a possibility. But there are a lot of things. If you compare the world in 2022 to where we are today in '24, just at a minimum taking masks out of the equation is a big difference. Having the ability to have in person investigator meetings, have the ability to do things that ensure rigorous adherence to the protocol, very exacting requirements of that protocol consistently across sites. All those things combined have the potential, of course, to improve even on what we've seen in the past in Phase 2 and in PALISADE-2. Josh Prince, you want to add anything to that?
Josh Prince: Sure, Shawn. Thank you. Yeah, I think we're very optimistic about our ability to execute a well- controlled study post-pandemic and it's everything that you talked about, but it's also the things that we're able to do in terms of how we work with our CRO. We're putting feet on the ground in terms of our own monitors going to sites in addition to CRO monitors. We have some additional exclusion criteria to make sure that subjects that are coming into the study have the best chance to have positive results or opportunity to have positive results with fasedienol and even things such as eligibility review, making sure that subjects are appropriate subjects before they're going into the Visit 2 and Visit 3 public speaking challenges. So you put all those things together and it does give us a fair amount of optimism moving into PAL-3 and PAL-4 compared to what we had when we were executing PALISADE-1 and PALISADE-2.
Andrew Tsai: Thanks. And maybe a follow-up on the repeat dose study that you're initiating in second half. As we think about the three arms, what are you and the FDA looking for or said in another way, what is positive data to you?
Shawn Singh: Josh, go ahead and address that.
Josh Prince: Yeah, we expect it to be a smaller study. So, it's not at this point, we don't expect to see, power for statistical significance like you would in the PALISADE-3 or PALISADE-4, but it would give us is, is there any is there any indication that for some patients an additional dose within 10 minutes could provide some benefit and that essentially can inform the label. So, at the end of the day for us positive study is we either see that there is some indication that it could be a benefit or we don't, but either way, there's benefit from the first dose.
Shawn Singh: Yeah, again, it's really the discussions have been circled around informing labelling downstream and also real-world understanding and some of that taken from open label activity where people might think more is better within a short period of time. So first and foremost, we have to check the box on safety, which again we don't think there's much of if any risk there associated with a second dose within that 10-minute window. For those who don't know, there's three arms before a public speaking challenge. Placebo, placebo drug, placebo drug, drug, each of the second doses within 10 minutes of the first and that's up front of public speaking challenges. So again, taking into account possibilities in the real world that people will use the drug a couple of times rather than staggered as the 15-minute study paradigm required or showed. So we'll see how it goes. Again, it's a dialogue. It's nice to be knowing we're talking about potential labelling benefits. So that's how we took it. These remember -- these receptors are activated in milliseconds. So it doesn't take much time to get them moving in the first instance.
Operator: [Operator instructions] Our next question comes from the line of Tim Lugo with William Blair. Please proceed with your question.
Tim Lugo: Thanks for the question and congratulations on the progress. For fasedienol, given a non-systemic, non-abusable profile and with a positive PAL-2 trial, could you look to gain breakthrough status with the agency? Is it something you're exploring? If you were to get breakthrough status, is it something that could impact your development path at all? And in your discussions with the agency, do you have enough maybe I guess preclinical data around abusability or enough animal data around abusability to have that included in the label?
Shawn Singh: Thanks Tim. Appreciate those questions. So, first as to BTD or breakthrough, look, that's always an aspiration of any company that's got something in a space that we've got. It's always an advocacy matter with the agency. I think, like I said, we just got done doing something we don't think anybody else has ever done that we've seen and we've certainly got a product profile potential that is different than anything that we see out there. We know the agency is worried about the potential high abuse of benzodiazepines given their drug safety communication on that during COVID. We also know that unfortunately social anxiety disorder and other anxiety disorders lead to depression and then lead, unfortunately, with increasing prevalence that we are seeing to suicidal ideation. So we already know we have fast-track. It doesn't mean that you necessarily fall into breakthrough, but certainly something on our mind. And you're right too that it is important whether or not we see this drug as potentially being scheduled. As we addressed a while back, especially with a drug that is administered intranasally, one might think, well, is it is there some abuse potential there? As we know from the preclinical work we've done and that we submitted to the FDA and also clinical work, a large body of work, including the open label study about 500 subjects with over 30,000 doses, we just were not seeing TEAEs or any certainly no SAEs that are usually associated with abuse liability, even in the longer-term open label. Mechanistically, it makes sense because the drug isn't taken up systemically and most importantly, based on the GABA study that we did preclinically and the C14 studies that we did, there's not tissue distribution and direct activity on the abuse liability receptors in the brain, opiate, nicotine, dopamine and the like and not potentiating GABA, like say a benzo would also worked in our favor. So I think we're very confident as we continue to see clinical data support the preclinical data and the whole package that says this is a differentiated safety profile because of the MOA. We're confident in a go-forward where patients could have the ability to access the drug online on a recurring basis with the drug potentially not being scheduled, no REMS. So we'll see how that continues to go, but what we saw in PALISADE-2, again, no TEA, more prevalent than 2%. In the large open label study, nothing more prevalent than 5% other than headache at 8.7%. So that's remarkably different than what we often hear when we're listening to commercials and side effects that are associated with particular therapeutic options.
Operator: There are no further questions in the queue. I'd like to hand the call back to Mark McPartland for closing remarks.
Mark McPartland: Thank you again, everyone for participating on the call today. Again, if you have any additional questions, please do not hesitate to contact us by email at ir@vistagen.com or contacting the individuals listed in our press release issued earlier today or the contact section of our website. Again, we also encourage you to register for email updates on our website to stay connected with the latest news from Vistagen and any future events. Thank you for participating on the call today. We appreciate everyone's interest and support. We look forward to keeping you current on our continued progress. This concludes the call. Have a tremendous day.
Operator: Ladies and gentlemen, this does include today's teleconference. Thank you for your participation. You may disconnect your lines at this time and have a wonderful day.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.